Comparison tool
Compare peptides
Pick up to three compounds. Useful for deciding whether two peptides in a stack actually do different things, or whether you're paying twice for the same pathway.
Select up to three (1/3)
| Attribute | |
|---|---|
| Category | Growth hormone |
| Evidence grade | Moderate |
| Also known as | Modified GRF 1-29, DAC:GRF |
| Mechanism | Binds pituitary GHRH receptors to increase both the amplitude of GH pulses and total GH secretion. The DAC (drug affinity complex) version binds serum albumin, extending the half-life from minutes to about a week. |
| Key benefits | Elevated GH and IGF-1 across the dosing window · Improved sleep depth reported by most users · Supports lean mass retention and fat oxidation |
| Side effects | Water retention · Tingling or numbness in hands · Head rush and flushing after injection · Elevated fasting glucose at higher doses |
| Half-life | ~30 minutes without DAC; ~6–8 days with DAC |
| Administration | Subcutaneous injection, typically before bed on an empty stomach |
| Dosing overview | 100 mcg (no-DAC) 1–3× daily, or 1–2 mg weekly for the DAC version |
| Storage | Refrigerate reconstituted product; protect from light and avoid shaking |
| Legal status | Not FDA-approved. Prescribed off-label by some clinics; banned in sport. |
Dosing figures reflect published literature and commonly reported community protocols. They are informational only.